YM BioSciences Cleared by FDA to Initiate Phase III Registrational Trial for Breast Cancer Drug
Pivotal trial to confirm previous positive phase III results for tesmilifene
06-Nov-2003 -
YM BioSciences Inc. , a cancer drug development company with an advanced-stage portfolio, announced that it has received written confirmation from the U.S. Food and Drug Administration (FDA) that it may initiate a pivotal Phase III, or registrational trial, for its lead small-molecule anti-cancer ...
breast cancer
cyclophosphamide
drug development
+3